According to the Zhitong Finance App, Kyodo Pharmaceutical (300966.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 346 million yuan, an increase of 14.51% over the previous year. The net loss attributable to shareholders of the listed company was RMB 32.8413 million, and the net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was RMB 32.6654 million.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.